GeneDx beat Q2 estimates, raised guidance, and is seeing rapid test volume growth and stronger reimbursements. Check out why ...

That earnings report, unveiled well before market open that day, revealed that GeneDx booked nearly $103 million in revenue.

The most assertive raise of the three came from BTIG's Mark Massaro, who now feels GeneDx is worth $125 per share, well up ...

GeneDx published data in JAMA from a cohort of more than 1300 patients with CP and found that exome and genome sequencing delivered a more than 30% diagnostic rate for these patients.

Shares in genetic testing company GeneDx Holdings (NASDAQ: WGS) continued their wild ride in 2025 and are up almost 34% on the week to Friday morning. This week's move follows the American Academy ...

Lavelle TA, Feng X, Keisler M, et al. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. Genet Med. 2022;24 (6):1349-1361. doi: 10.1016/j.gim.2022 ...

GeneDx pioneered whole exome sequencing in December 2012, and in the last 18 months alone has sequenced more than a third of the half million exomes. These test results, and corresponding clinical ...

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at ...